These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37728861)

  • 1. A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis.
    Harrold LR; Zueger P; Nowell WB; Blachley T; Schrader A; Lakin PR; Curtis D; Stradford L; Venkatachalam S; Tundia N; Patel PA
    Rheumatol Ther; 2023 Dec; 10(6):1519-1533. PubMed ID: 37728861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
    Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
    Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry.
    Baker JF; Zueger P; Ali M; Bennett D; Yu M; Munoz Maldonado Y; McLean RR
    Rheumatol Ther; 2024 Apr; 11(2):363-380. PubMed ID: 38345715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
    Strand V; Schiff M; Tundia N; Friedman A; Meerwein S; Pangan A; Ganguli A; Fuldeore M; Song Y; Pope J
    Arthritis Res Ther; 2019 Dec; 21(1):263. PubMed ID: 31791386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M
    Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
    Strand V; Tundia N; Bergman M; Ostor A; Durez P; Song IH; Enejosa J; Schlacher C; Song Y; Fleischmann R
    Rheumatology (Oxford); 2021 Dec; 60(12):5583-5594. PubMed ID: 33590829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry.
    Gavigan K; Nowell WB; Serna MS; Stark JL; Yassine M; Curtis JR
    Arthritis Res Ther; 2020 Jan; 22(1):4. PubMed ID: 31910893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
    Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V; Mease PJ; Soriano ER; Kishimoto M; Salvarani C; Saffore CD; Zueger P; McDearmon-Blondell E; Kato K; Gladman DD
    Rheumatol Ther; 2021 Dec; 8(4):1789-1808. PubMed ID: 34636026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
    Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.
    Curtis JR; Yun H; Chen L; Ford SS; van Hoogstraten H; Fiore S; Ford K; Praestgaard A; Rehberg M; Choy E
    Rheumatol Ther; 2023 Aug; 10(4):1055-1072. PubMed ID: 37349636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
    Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
    Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology.
    Yun H; Nowell WB; Curtis D; H Willig J; Yang S; Auriemma M; Chen L; Filby C; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):553-560. PubMed ID: 30927515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
    Pope J; Bingham CO; Fleischmann RM; Dougados M; Massarotti EM; Wollenhaupt J; Duncan B; Coteur G; Weinblatt ME
    Arthritis Res Ther; 2015 Nov; 17():343. PubMed ID: 26614481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study.
    Bessette L; Chan J; Chow A; Lisnevskaia L; Richard N; Fournier PA; Liazoghli D; Girard T; Haaland D
    Rheumatol Ther; 2024 Jun; 11(3):563-582. PubMed ID: 38467912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
    Strand V; Van den Bosch F; Ranza R; Leung YY; Drescher E; Zueger P; Saffore CD; Lertratanakul A; Lippe R; Nash P
    Rheumatol Ther; 2021 Dec; 8(4):1827-1844. PubMed ID: 34661885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis.
    Harrold LR; John A; Reed GW; Haselkorn T; Karki C; Li Y; Best J; Zlotnick S; Kremer JM; Greenberg JD
    Rheumatol Ther; 2017 Dec; 4(2):405-417. PubMed ID: 28936808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis.
    Navarro-Compán V; Baraliakos X; Magrey M; Östör A; Saffore CD; Mittal M; Song IH; Ganz F; Stigler J; Deodhar A
    Rheumatol Ther; 2023 Jun; 10(3):679-691. PubMed ID: 36820984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
    Pappas DA; O'Brien J; Guo L; Shan Y; Baker JF; Kricorian G; Stryker S; Collier DH
    Arthritis Res Ther; 2023 Sep; 25(1):166. PubMed ID: 37689684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
    Strand V; Tundia N; Wells A; Buch MH; Radominski SC; Camp HS; Friedman A; Suboticki JL; Dunlap K; Goldschmidt D; Bergman M
    Rheumatology (Oxford); 2021 Jul; 60(7):3209-3221. PubMed ID: 33313898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.